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Abstract 
TP53 is one of the most commonly mutated genes in human tumours. Variations in the types 
and frequencies of mutations at different tumour sites suggest that they may provide clues to the 
identity of the causative mutagenic agent. A useful model for studying human TP53 mutagenesis is 
a partial human TP53 knock-in (Hupki) mouse containing exons 4−9 of human TP53 in place of the 
corresponding mouse exons. For an in-vitro assay, embryo fibroblasts from the Hupki mouse 
(HUFs) can be examined for the generation and selection of TP53 mutations, as mouse cells can be 
immortalised by mutation of Tp53 alone. Thus far four environmental carcinogens have been 
examined using the HUF immortalisation assay: (i) UV light, which is linked to human skin cancer; 
(ii) benzo[a]pyrene, which is associated with tobacco smoke-induced lung cancer; (iii) 3-
nitrobenzanthrone, a suspected human lung carcinogen linked to diesel exposure; and (iv) 
aristolochic acid, which is linked to Balkan endemic nephropathy-associated urothelial cancer. In 
each case a unique TP53 mutation pattern was generated that corresponded to the pattern found in 
human tumours where exposure to these agents has been documented. Therefore, the HUF 
immortalisation assay has sufficient specificity to make it applicable to other environmental 
mutagens that putatively play a role in cancer aetiology. Despite the utility of the current HUF 
immortalisation assay, it has several limitations that could be addressed by future developments, in 
order to improve its sensitivity and selectivity. 
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Abbreviations:  
AA, aristolochic acid; AAN, aristolochic acid nephropathy; B[a]P, benzo[a]pyrene; BEN, Balkan 
endemic nephropathy; BPDE, benzo[a]pyrene-7,8-diol-9,10-epoxide; CYP, cytochrome P450; 
DBD, DNA-binding domain; HUF, Hupki embryo fibroblast; Hupki, Human TP53 knock-in; LM-
PCR, ligation-mediated PCR; MEF, mouse embryo fibroblast; 3-NBA, 3-nitrobenzanthrone; NER, 
nucleotide excision repair; PAH, polycyclic aromatic hydrocarbon; ROS, reactive oxygen species; 
WT, wild-type; UV, ultraviolet; Xpa, Xeroderma pigmentosum group A. 
 
 4
Introduction 
 Environmental factors including dietary habits and lifestyle choices play important roles in 
most human cancers, tempered by interindividual variation in susceptibility [1,2]. Cancer is a 
disease characterised by a series of genetic alterations that result in the loss of cellular growth, 
proliferation and differentiation control [3]. These genetic alterations include somatic mutations in 
DNA that may arise as a result of chemical action by agents of either endogenous (e.g. reactive 
oxygen species [ROS]) or exogenous (e.g. environmental carcinogens) origin. Initiation of 
carcinogenesis can occur through activating mutations in oncogenes (e.g. RAS), which encode 
proteins that promote cell proliferation and survival, and/or inactivating mutations in tumour 
suppressor genes (e.g. TP53), which encode proteins that normally suppress cell growth [4]. 
Initiated cells undergo clonal expansion as they are promoted by their microenvironment and 
accumulate additional mutations that endow the population with invasive, metastatic and angiogenic 
capabilities. 
 The most commonly mutated gene in cancer is the tumour suppressor TP53. Somatic 
mutations in TP53 have been found in approximately 50% of human cancers [5], and rare TP53 
germline mutations (e.g. Li-Fraumeni syndrome) predispose carriers to various tumour types [6]. 
There is a large and diverse spectrum of TP53 mutations that can lead to altered function of the 
gene product and contribute to malignant transformation. This diversity contrasts with other 
commonly mutated genes, such as RAS, where activating mutations occur in only a few codons of 
the gene [7]. Therefore, mutation spectra in TP53 may be especially informative in attempting to 
understand the origin of mutations in human tumours.  
  TP53 encodes for the protein p53 that functions predominantly as a transcription factor, 
although other activities have been described [8]. Mice with genetic deletion of Tp53 develop 
normally but are tumour prone, suggesting that p53 is not essential for normal cell growth but acts 
to prevent the growth of abnormal cells [9]. In normal, unstressed cells p53 protein expression is 
kept low via ubiquitin-mediated proteolysis that is regulated by the E3 ubiquitin ligase MDM2 [10]. 
However, p53 protein accumulates in response to various stresses, such as DNA damage, activation 
of oncogenes or hypoxia [11,12]. This occurs via post-translational modifications (e.g. 
phosphorylation and acetylation) that inhibit the interaction of p53 and MDM2 and can regulate its 
activity and location in the cell [13]. Once p53 is stabilised and activated it coordinates an 
appropriate response by activating the transcription of a variety of genes involved in cell cycle 
arrest, DNA repair, senescence and apoptosis [14,15]. For example, in response to genotoxic stress, 
p53 can transiently arrest the cell cycle at G1 or G2, such as by inducing the expression of 
p21WAF1/Cip1, a cyclin-dependent kinase inhibitor [16]. This allows time for the cell to survey and 
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repair the damage, and prevents damaged cells from dividing. p53 can also induce senescence, 
which is a permanent G1 arrest. In cells that have been severely damaged, p53 may activate 
apoptosis by stimulating the transcription of genes such as PUMA and NOXA [17]. Disruption of 
the normal p53 response by TP53 mutation contributes to transformation by eliminating the cell’s 
braking mechanism in the face of stress and oncogenic activation. 
    
TP53 mutations can be linked to cancer aetiology 
 Around 25,000 TP53 mutations in human tumours have been registered in the International 
Agency for Research on Cancer (IARC) TP53 database (www.p53.iarc.fr) providing an important 
resource for studying the types and frequencies of mutations in human tumours [18]. TP53 contains 
11 exons but most mutations are of the missense type in exons 5−8, which code for the DNA 
binding domain (DBD) of p53. Of the 1150 possible missense mutations in the DBD, 999 have 
been reported in tumours, as well as all 58 possible nonsense mutations [18]. Amidst the great 
variety of TP53 mutations, several patterns have emerged [19]. The TP53 mutations that are 
manifest in human tumours have been shaped by a combination of (i) the origin of the mutation 
(e.g. type of mutagen), (ii) the sequence of TP53, (iii) efficiency of lesion repair, and (iv) the 
selection for mutations that disrupt the normal function of p53. In principle, this information can be 
used to generate hypotheses regarding disease risk factors in a defined population [18].  
 Mutation patterns and spectra in TP53 are often cancer specific [19], suggesting that 
environmental exposures may lead to a specific signature of mutations. Three often-cited 
observations that draw a link between a particular mutation profile and specific environmental risk 
factors are: (a) basal and squamous cell skin carcinomas caused by exposure to ultraviolet (UV) 
light that contain a high prevalence of tandem CC to TT transitions in TP53 [20,21]; (b) lung 
tumours of tobacco smokers (but not of non-smokers) that contain a high percentage of G to T 
transversions in TP53 at several hotspot locations, characteristic of polycyclic aromatic 
hydrocarbons (PAHs) present in tobacco smoke [22,23]; and (c) hepatocellular carcinoma from 
high incidence areas where aflatoxin exposure and chronic hepatitis B infection are common, that 
predominantly contain a G to T transversion at codon 249 of TP53 [24,25]. More recently, a high 
prevalence of A to T transversions in TP53 has been found in urothelial carcinoma associated with 
Balkan endemic nephropathy (BEN) and linked to exposure to aristolochic acid (AA) [26,27].  
 Base chemistry and sequence context play a key role in chemical- and UV-induced 
mutagenesis of TP53. One of the most important influences in the TP53 sequence is the presence of 
CpG dinucleotides. The TP53 DBD contains 23 CpG dinucleotides, all of which are methylated in 
human tissues [28]. Thirty-three percent of TP53 DBD mutations and six major hotspots (codons 
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R175, R213, G245, R248, R273, and R282) occur at methylated CpG sites [29]. These sites are 
inherently promutagenic for two main reasons. Firstly, spontaneous deamination of 5-
methylcytosine creates thymine and is thought to be a main source of C to T transitions in internal 
cancers [30]. Secondly, certain environmental carcinogens, such as PAHs, preferentially bind to 
guanines in methylated CpG sites, and UV irradiation often modifies methylated cytosines [31-33]. 
Thus, in cells exposed to such factors, mutations within methylated CpG sites may be most 
common. 
 The observed spectrum of TP53 mutations has been further shaped by selection for mutants 
that exhibit loss-of-function and dominant-negative effects or, in some cases, gain-of-function. 
Approximately 80% of the TP53 DBD missense mutations in tumours code for a protein with little 
or no transactivational capacity as shown using a yeast-based functional assay [34]. These mutants 
also commonly exert dominant-negative effects against wild-type (WT) p53 [18]. Mutations that 
have the greatest impact on p53 function will be selected for in tumourigenesis. For example, of the 
34 possible missense mutations arising from transitions at CpG sites in the TP53 DBD, only seven 
are frequently observed in tumours [35,36]. These are located in codons for amino acids which 
either bind directly to the DNA of target genes (R248, R273) or are critical for stabilising the 
interaction of p53 with DNA (R175, R282, G245) [37]. These seven mutations severely affect the 
ability of p53 to activate its transcriptional targets, whereas 24 of the other 27 rarer mutants retain 
transactivational capacity [34].  
 
The human TP53 knock-in (Hupki) mouse: an experimental model to study human TP53 
mutagenesis 
 The frequency and variety of TP53 mutations in human cancer make it a useful target gene 
for experimental mutagenesis. A useful model for studying human TP53 mutagenesis is a partial 
human TP53 knock-in (Hupki) mouse (The Jackson Laboratory Repository designation: 
129Trp53tm/Holl) containing exons 4−9 of human TP53 in place of the corresponding mouse exons 
(Figure 1) [38]. This mouse expresses a chimeric p53 protein that functions normally, whereas the 
p53 product of a full-length human TP53 mouse model was functionally deficient [39]. Hupki mice 
homozygous for the knock-in allele do not develop spontaneous tumours at an early age, in contrast 
to Tp53-null mice [38]. Additionally, Hupki mice did not differ in tumour response from their 
counterparts with murine Tp53 in a N-nitrosodiethylnitrosamine-induced hepatocarcinogenesis 
model [40]. Further, gene expression profiles from the spleens of untreated and γ-irradiated Hupki 
mice were highly concordant to those of WT mice, and key p53-target genes such as Bax, Mdm2, 
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and Cyclin G were induced by γ-irradiation. This indicates that the DNA damage response and 
transcriptional activities of p53, at least in the spleen, are similar in both mouse strains [38].  
The Hupki mouse is useful for both in-vitro and in-vivo studies of TP53 mutations induced 
by carcinogens. The nucleotide sequence of the mouse Tp53 DBD differs by 15% from the human 
sequence, and this difference may greatly impact experimentally-induced mutation spectra [41]. 
Thus, mice, and cells derived from them, containing the human TP53 DBD sequence can be used to 
test hypotheses on the origin of TP53 mutations found in human tumours [38,42].  
For an in-vitro assay, embryo fibroblasts from the Hupki mouse can be examined for the 
generation and selection of TP53 mutations. The challenge in creating a mammalian cell mutation 
assay using TP53 as a target gene is to identify a strategy for selecting mutated cells. Commonly 
used in vitro mutation assays that utilise either non-mammalian genes (e.g. lacI, lacZ) [43] or 
human genes with no known role in cancer (e.g HPRT) [44], generally involve manipulating growth 
conditions to favour the mutated cells. In order to select for TP53-mutated cells Hollstein and 
coworkers [38,45] exploited the fact that cultured mouse embryo fibroblasts (MEFs), in contrast to 
human fibroblasts, can be immortalised by mutation of Tp53 alone.  
MEFs undergo p53-dependent senescence after approximately 10 population doublings 
when cultured under standard conditions (20% atmospheric oxygen). This appears to occur in 
response to accumulated oxidative damage, as MEFs grown at physiological oxygen tension (3% 
oxygen) do not senesce (Figure 2) [46]. However, mouse fibroblasts which develop mutations in 
certain genes, such as Tp53, can bypass senescence and become immortalised [47,48]. The 
immortalisation of human cells is more complex. Cultured human cells proliferate for 50 or more 
population doublings at 20% oxygen before entering replicative senescence, which is regulated by 
both the p53 and p16INK4a/pRB pathways, and they do not undergo immortalisation spontaneously 
[49,50]. If replicative senescence is bypassed by mutation or expression of viral oncogenes, human 
cells will only divide for further 10-20 population doublings before entering a second process 
termed ‘crisis’ [50]. Replicative senescence and ‘crisis’ of human cells is due to shortening of 
telomeres. Human cells, unlike mouse cells, do not express telomerase, thus immortalisation 
requires reconstitution or upregulation of telomerase activity, in addition to alterations in the p53 
and p16INK4a/pRB pathways [51,52]. Therefore, unlike mouse fibroblasts, human cells cannot be 
immortalised in culture simply by disruption of TP53.  
In order to study TP53 mutagenesis, Hupki embryo fibroblast (HUF) cultures are treated 
with a mutagen to induce TP53 mutations (Figure 2). The treated cultures, along with untreated 
control cultures, are then serially passaged in 20% oxygen. Cells containing mutations (e.g. in 
TP53) that allow bypass of p53-dependent senescence become established into immortalised 
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cultures, while the majority of cells undergo irreversible growth arrest and are selected against. A 
detailed protocol for the HUF immortalisation assay has been published [42], and when these 
guidelines are followed each culture of 0.4–2 × 105 primary HUFs (untreated or mutagen-treated) 
will result in an immortal cell line. Untreated cultures are thought to undergo spontaneous 
immortalisation due to mutations induced by the cell culture conditions (e.g. DNA damage by ROS 
resulting from growth at 20% oxygen). DNA from the immortal HUF clones can then be sequenced 
to identify TP53 mutations. The mutations identified in HUF clones derived from mutagen 
exposure can then be compared with the profile of mutations found in tumours of individuals who 
were exposed to the agent of interest. Most HUF mutants identified to date are classified as “non-
functional” according to a yeast-based functional assay, which is in accordance with the majority of 
human tumour mutations (see Supporting Table S1) [34,53]. Additionally, HUF mutant clones can 
be directly evaluated for the impact of each mutation on the ability of p53 to transactivate target 
genes (i.e. Cdkn1a, Puma, Noxa). Indeed, it was recently shown that a set of TP53 mutant HUF cell 
lines lost their ability to induce p53 target genes, while HUF clones with WT TP53 generally 
retained transactivational activity [53].. 
 
Investigating human cancer aetiology using the HUF immortalisation assay 
 Thus far four environmental carcinogens have been examined using the HUF 
immortalisation assay: (i) UV light, (ii) benzo[a]pyrene (B[a]P), (iii) 3-nitrobenzanthrone (3-NBA) 
and (iv) aristolochic acid I (AAI) (Figure 3) [54-59]. In each case a unique TP53 mutation pattern 
was generated in the HUF immortalisation assay that differed from that found in control HUFs that 
had undergone spontaneous immortalisation.  
 
UV-induced human skin cancer 
 The major aetiological agent contributing to non-melanoma skin cancer is sunlight, which 
includes UV frequencies [20,21]. TP53 is frequently mutated in these tumours, and C to T or CC to 
TT transitions at dipyrimidine sites have been observed as signature mutations after UV-irradiation. 
Hotspot mutations were located at codons 151/152, 245, 248, 278 and 286 in TP53 [60]. Two major 
types of DNA photoproducts, cyclobutane pyrimidine dimers (CPDs) and (6-4) pyrimidine-
pyrimidone photoproducts [(6-4)PPs] (Figure 4), have been mapped in TP53 in UV-irradiated 
human cells at the DNA sequence level using ligation-mediated polymerase chain reaction (LM-
PCR). UV-induced DNA adducts were found most frequently at codons 151, 278 and 286 [60]. 
When HUFs were exposed to UV prior to selecting for immortalisation, five out of 20 HUF cell 
lines generated contained TP53 mutations; all five carried base changes at dipyrimidine sites of 
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TP53 (a total of eight TP53 mutations were detected) (Figure 3) [54]. The major mutation type 
induced was a C to T transition, the hallmark mutation in UV-induced mutagenesis. Interestingly, 
one UV-derived HUF harboured 3 single-base substitutions at codons 248, 249 and 250, one of 
which (248) is a hotspot location in human skin cancer [54].  
  
Tobacco smoke-associated lung cancer 
 Tobacco smoking causes lung cancer and tobacco smoke contains many thousands of 
chemicals, including carcinogenic PAHs such as B[a]P [61]. B[a]P is metabolically activated by 
cytochrome P450 (CYP) enzymes (e.g. CYP1A1, CYP1B1) and epoxide hydrolase to the ultimately 
reactive metabolite B[a]P-7,8-diol-9,10-epoxide (BPDE) [62] that reacts primarily at the N2 
position of guanine in DNA (dG-N2-BPDE) (Figure 4). Using the HUF immortalisation assay 28 
HUF cell lines were derived from B[a]P treatment carrying a total of 37 TP53 mutations [55,57; M. 
Hollstein, personal communication]. The predominant mutation type was G to T transversion 
accounting for 49% of the total, followed by G to C (22%) and G to A (19%) mutations (Figure 
5A). Codons 157 and 273 account for ten of the mutations (five each) (Figure 5A).  
 The mutation pattern observed in human lung cancer from smokers is dominated by the 
presence of G to T transversions (30%), followed by G to A transitions (26%), and the distribution 
of mutations along TP53 is characterised by several hotspots, in particular at codons 157, 158, 175, 
245, 248 and 273 (Figure 5B). At several TP53 mutational hotspots that are common to all cancers, 
such as codons 248 and 273, a large fraction of mutations in lung cancer are G to T events but are 
almost exclusively G to A transitions in non-tobacco-related cancers [22]. Whereas G to A 
mutations can arise through deamination of methylated cytosines, G to T transversions can be a 
consequence of misreplication of bases covalently modified by bulky carcinogens, such as B[a]P 
and other PAHs. Using LM-PCR selective DNA adduct formation was observed at guanine 
positions in codons 157, 248 and 273 in TP53 of normal human bronchial epithelial cells treated 
with BPDE [63]. Subsequently, mapping of other PAH-derived DNA lesions yielded mostly similar 
results [64], suggesting that the overall spectrum of TP53 mutations in lung cancer of smokers is 
determined by exposure to multiple PAHs, possibly having additive or multiplicative effects. 
Interestingly, the G to T transversions observed in codons 157, 248 and 273 are at sites containing 
methylated CpG dinucleotides (all CpG sites in the DBD of TP53 are completely methylated) [22]. 
It has been proposed that methylation at CpG sites may increase the potential for planar carcinogen 
compounds to intercalate prior to covalent binding, although the precise mechanism still needs to be 
determined. Furthermore, the majority of G to T transversions occur on the non-transcribed DNA 
strand, particularly at hotspot codons 157, 158 and 273, which may be linked to the fact that B[a]P-
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derived DNA adducts are removed less efficiently from the non-transcribed strand than from the 
transcribed strand of this gene [23,65]. As already described, in cell lines from B[a]P-treated HUFs, 
codons 157 and 273 are also recurrent sites of mutation (Figure 5A) with a significant proportion of 
these mutations being G to T [57]. Consequently, the data collected in the HUF immortalisation 
assay are consistent with the hypothesis that B[a]P has a direct role in causing smokers’ lung 
tumour TP53 mutations. 
 
3-Nitrobenzanthrone, a potential human lung cancer hazard in diesel exhaust and urban air 
pollution 
 Epidemiological studies suggest that air pollution may increase lung cancer risk [66]. Nitro-
PAHs are present on the surface of ambient air particulate matter and diesel exhaust particles [67] 
and their detection in lungs of non-smokers with lung cancer has led to considerable interest in 
assessing their potential risk to humans [68]. The aromatic nitroketone 3-NBA (Figure 4) is one of 
the most potent mutagens and potential human carcinogens identified in diesel exhaust and ambient 
air pollution [69-71]. Indeed, 3-NBA induces squamous cell carcinoma in rat lung after 
intratracheal administration [70]. 3-NBA forms DNA adducts after metabolic activation through 
reduction of the nitro group, which is primarily catalysed by NAD(P)H:quinone oxidoreductase 
(NQO1) [72,73]. It can be further activated by N-acetyltransferase and sulfotransferases [72,74]. 
The predominant DNA adducts detected in vivo in rodents after treatment with 3-NBA are 2-(2’-
deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-3-ABA) and N-(2’-deoxyguanosin-8-yl)-3-
aminobenzanthrone (dG-C8-N-3-ABA) [75,76] (Figure 4), and these are most probably responsible 
for the G to T transversion mutations induced by 3-NBA in transgenic MutaMouse [77].  
 Using the HUF immortalisation assay 19 cell lines carrying a total of 29 TP53 mutations 
were derived from 3-NBA treatment [59]. The major mutation type induced by 3-NBA was G to T 
transversion (38%), followed by A to G (24%) and G to C (17%) mutations (Figure 5C). Although 
G to T transversions were also the predominant mutations found in B[a]P-treated HUFs, the 
mutation spectra for 3-NBA and B[a]P were significantly different [59], indicating that each 
carcinogen likely has a characteristic mutation signature. A large number of 3-NBA-induced 
mutations were found at adenine residues (total 44%), which is in line with the fact that 3-NBA also 
binds covalently at adenine (e.g. 2-(2’-deoxyadenosin-N6-yl)-3-aminobenzanthrone) [75], although 
nothing is yet known about the mutagenic potential of those adducts using a site-specific 
mutagenesis assay.  
 In lung tumours of non-smokers G to A transitions (40%) and G to T transversions (17%) 
are the prominent types of mutations induced (Figure 5D). G to T transversions have also been 
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detected at high frequency in the lungs of gpt-delta transgenic mice following inhalation of diesel 
exhaust [78]. Furthermore, in the same model the mutations induced by 1,6-dinitropyrene, another 
nitro-PAH present in diesel exhaust, were mainly G to A transitions and G to T transversions [79]. 
Therefore, it is tempting to speculate that nitro-PAHs, including 3-NBA, may contribute to the 
induction of G to T mutations in lung tumours of non-smokers.  
 
Aristolochic acid-exposed human urothelial cancer 
 The herbal drug AA, which comes from the genus Aristolochia, has been associated with the 
development of a novel human nephropathy, known as aristolochic acid nephropathy (AAN), and 
its associated urothelial cancer [80,81]. AAI (Figure 4) is the major component of the plant extracts. 
AAN was first reported in Belgian women who had consumed Chinese herbs as part of a weight-
loss regimen in 1991 and was traced to the ingestion of Aristolochia fangchi inadvertently included 
in the slimming pills [81]. Within a few years of taking the pills, AAN patients had developed a 
high risk of upper tract urothelial carcinoma (about 50%) [82] and, subsequently, bladder urothelial 
carcinoma [83]. Using the highly sensitive 32P-postlabelling assay, exposure to AA was 
demonstrated by the identification of specific AA-DNA adducts in urothelial tissue of AAN patients 
[82,84,85]. Further, chronic exposure to Aristolochia clematitis has been linked to BEN and its 
associated urothelial cancer [26,27]. This nephropathy is endemic in certain rural areas of Serbia, 
Bosnia, Croatia, Bulgaria and Romania. BEN is clinically and morphologically very similar to 
AAN; indeed, AA-specific DNA adducts have been detected in BEN patients and in individuals 
with end-stage renal disease living in areas endemic for BEN [27,86], suggesting that dietary 
exposure to AA is a risk factor for the development of the disease.  
 The major activation pathway of AA is reduction of the nitro group (Figure 4). Cytosolic 
NQO1 has been shown to be the most efficient enzyme, although CYP1A1, CYP1A2 and 
prostaglandin H synthase (cyclooxygenase, COX) are also able to metabolically activate AA [87]. 
The most abundant DNA adduct detected in AAN and BEN patients is 7-(deoxyadenosin-N6-
aristolactam I (dA-AAI), and A to T tranversion mutations in TP53 are found in the urothelial 
tumours associated with both pathologies (see below) [27,88]. In-vitro experiments using terminal 
tranferase-dependent PCR (TD-PCR) analysis have revealed that AA preferentially binds to purine 
bases within TP53 [89].   
To date 32 immortalised HUF cell lines have been derived from AAI treatment carrying a 
total of 37 TP53 mutations [54,56,58]. The AAI-induced TP53 mutation pattern is dominated by A 
to T transversions (57%) (Figure 6A). One of the experimentally-induced A to T mutations (at 
codon 139) matches the TP53 mutation reported in a urothelial carcinoma of an AAN patient in the 
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UK [88]. In urothelial tumours of BEN patients from Croatia (n=11), mutations at A:T pairs 
accounted for 89% (17/19) of all mutations, with the majority of these (15/17) being A to T 
transversions, representing 78% of all base substitutions detected in TP53 (Figure 6B) [27]. In 
contrast, A to T transversions account for only around 5% of all the TP53 mutations in non AA-
associated human urothelial tumours (Figure 6C). Strikingly, eight of the A to T mutations in AAI-
treated HUFs (at codons 131 [2×], 209 [3×], 280, 286 and 291) are uncommon in the IARC TP53 
database but are identical to mutations found in urothelial tumours from BEN patients (at codons 
131, 209, 280 [3×], 286 and 291 [2×]) [27,58]. Given that the TP53 mutations in tumours of BEN 
patients correlate remarkably well with AAI-HUF experimental mutations, yet are of a type rare in 
other human urothelial tumours, this strongly suggests that AA plays a causative role in the 
aetiology of BEN-associated tumourigenesis [58]. IARC recently classified AA as a human (Group 
1) carcinogen (having previously classified it in Group 2A [probable human carcinogen] in 2000) 
[90]. This example illustrates how mechanistic data, including that obtained by the HUF 
immortalisation assay, can help to identify human carcinogenic hazards. 
 
Current limitations and possible future modifications for the HUF immortalisation assay 
Despite the utility of the current HUF immortalisation assay, it has several limitations that 
could be addressed by future developments. Firstly, the assay does not specifically select for TP53-
mutated cells, but rather for bypass of senescence induced by hyperoxic cell culture conditions. 
Modification of genes other than TP53 can allow MEFs to avoid the p53-controlled arrest induced 
by oxidative stress and to undergo immortalisation. For example, besides TP53 mutation, the most 
commonly found genetic alteration in immortalised MEFs is loss of the p19Arf locus [48]. However, 
a recent study showed that loss of p19Arf occurs in only 5% of spontaneously immortalised HUF cell 
lines compared with 17% of immortalised MEFs with the nascent Tp53 gene [53]. A number of 
other cancer-associated genes have been shown to regulate MEF senescence, including Mdm2, 
Cdk4, Tbx2, Bcl6, GSK3β, and several others [91-96]. The proportion of immortalised HUF clones 
with mutated TP53 is up to 20% in spontaneously immortalised cultures and up to 40% in treated 
cultures depending on the mutagen [53,57,59]. Thus, the majority of immortalised HUF cell lines 
do not contain TP53 mutations and the effort expended culturing these clones is fruitless. If 
possible, a new or additional selection procedure specific to the activity of only p53 would be a 
great improvement to the assay and further work will be required to develop such a procedure. 
An additional aspect of the assay to consider is the paradox presented by the growth of 
HUFs in 20% oxygen. On one hand, this level of oxygen is necessary to serve as the selective 
pressure for the growth of HUFs with mutant p53 in the immortalisation assay; conversely, growth 
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under atmospheric oxygen leads to oxidative damage and mutations [46]. Using a lacZ reporter 
gene, it has been shown that MEFs grown in 20% oxygen accumulate point mutations as they 
become immortalised. After 17 population doublings, the majority of mutations are G to T 
transversions, a signature mutation of oxidatively damaged DNA [97]. MEFs grown in 3% oxygen, 
on the other hand, do not accumulate such mutations over at least 20 population doublings. Thus, 
HUFs are likely to acquire ROS-induced DNA lesions throughout culturing and the immortalisation 
process at 20% oxygen, both before and after treatment with a mutagen. These mutations could be 
within TP53 itself, or in one of the other genes capable of regulating senescence, and may 
contribute to the background frequency (i.e. not induced by mutagen treatment) of mutation and 
immortalisation.  
In order to clarify the origin of mutations in the assay, it is necessary to compare the TP53 
mutation pattern of spontaneously immortalised HUFs (the untreated controls) to that of mutagen-
treated HUFs. Interestingly, previous studies have shown that the most common type of TP53 
mutation in the spontaneously immortalised HUFs is G to C transversion (Figure 3), whereas G to T 
transversion, the type most commonly associated with oxidatively-damaged DNA, is infrequent 
[53]. Although ROS-damaged DNA can also result in G to C transversions [98], it is as yet unclear 
why G to T transversions are not also common in TP53 in HUFs spontaneously immortalised by 
growth in 20% oxygen. Regardless, one would hypothesise that limiting the exposure of HUFs to 
hyperoxic conditions would be likely to reduce the level of background mutations, whatever type 
they may be, if the assumption that they are indeed caused by ROS is correct. Cells could be 
maintained under 3% oxygen both before and during mutagen treatment, and then transferred to 
20% oxygen to select for senescence bypass. Furthermore, if an alternative to incubation in 20% 
oxygen for selecting TP53-mutated cells were to be developed (see above), the entire assay could 
potentially be performed solely under 3% oxygen. 
Taking cues from other mutagenesis systems, such as the Salmonella Ames assay, further 
modifications to the HUF immortalisation assay could include (i) enhancement of xenobiotic 
metabolism to increase the range of chemical carcinogens which can be tested and (ii) modification 
of DNA repair processes to increase the mutation frequency. Xenobiotic metabolism, which is 
responsible for activating pro-carcinogens into DNA-reactive intermediates, can differ significantly 
between species and cell types [99]. HUFs have been shown to express many key metabolic 
enzymes, such as CYPs, but they have not been fully characterised and may be metabolically 
incompetent for some types of chemical pro-carcinogens [54]. For such compounds it could be 
advantageous to co-incubate cells with hepatic S9 fractions or isolated microsomes, which are 
enriched in many xenobiotic metabolism enzymes (e.g. CYPs) [100]. Alternatively, Hupki mice 
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could be created, by genetic engineering or crossbreeding, that express or over-express desired 
enzymes. For example, in mice expressing human CYP1A2 (knocked-in to replace the mouse gene) 
the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), is preferentially 
hydroxylated at the N2-position (i.e. activation), whereas in WT mice expressing innate Cyp1a2, 4’-
hydroxylation (i.e. detoxification) is the predominant pathway [101,102]. Thus, expression of 
human CYPs in Hupki mice could be an important refinement for assessing the mutagenic potential 
of selected compounds like PhIP that are not well activated by the nascent WT mouse enzymes.  
Finally, the assay could be made more sensitive by interfering with the ability of HUFs to 
repair certain types of DNA damage. This could be achieved by genetic engineering or by 
crossbreeding to generate Hupki mice deficient in nucleotide excision repair (NER) or base excision 
repair (BER). For example, mice deficient in the Xeroderma pigmentosum group A (Xpa) gene are 
defective in NER and highly susceptible to environmental carcinogens [103]. Many bulky DNA 
adducts (e.g. those formed by B[a]P, 3-NBA or AAI) are removed via the NER pathway and Xpa-
null mice exhibit increased mutation frequency in lacZ after treatment with adduct-forming 
compounds [104,105]. We have recently crossed Xpa-deficient mice with the Hupki mice in order 
to study the role of Xpa function and NER on the induction of TP53 mutations in HUFs. It is 
anticipated that DNA-repair deficient HUFs should be more susceptible to environmental mutagens, 
providing a more sensitive assay to screen for TP53 mutations. However, it may also be important 
to consider that mouse cells differ from human cells in some aspects of DNA repair, and this may 
affect the TP53 mutation spectrum observed in HUFs, perhaps depending on the type of mutagen. 
For example, mouse cells are deficient in the global genomic repair of UV-induced CPDs, which 
has been attributed to a lack of p48 protein expression [106]. Due to this deficiency, UV-induced 
skin tumours in hairless mice contain Tp53 mutations predominantly on the non-transcribed DNA 
strand, whereas in humans there is no strand bias [107].  
 
In-vivo Hupki studies 
 In addition to in-vitro studies, the Hupki mouse can be used to study in-vivo TP53 
mutagenesis in carcinogen-induced tumours [108,109]. The utility of such studies may be limited, 
however, because, with the exception of skin carcinomas, the majority of chemically-induced or 
spontaneous tumours in mice do not necessarily contain Tp53 mutations [110]. This observation is 
perplexing, considering the fact that both Tp53-null mice and mice genetically engineered to 
express mutant Tp53 readily develop tumours. The reason(s) for the discrepancy is still unclear, but 
several hypotheses have been proposed [110,111]. For instance, whether or not nascent mouse Tp53 
is found mutated in tumours appears to depend at least in part on the treatment protocol and target 
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organ. It may also depend on the genetic background of a given mouse strain, or on fundamental 
differences in the signalling pathways and/or regulation of growth control genes between mice and 
humans [111].  
 To date, only UVB irradiation of Hupki mice has resulted in tumours containing TP53 
mutations [108]. When Hupki mice were irradiated with a single acute dose of UVB, DNA lesion 
footprinting showed an accumulation of UV photoproducts in their epidermal DNA at the same 
locations within TP53 as were found in human cells [108]. Furthermore, after chronic UVB 
exposure for several weeks Hupki skin epidermal cells harboured C to T and CC to TT transitions at 
two mutation hotspots (codons 247/248 and 278/279) identified in human skin cancer [108]. In 
contrast, no Tp53 mutations were found at sequences equivalent to human codons 247/248 in UVB-
induced skin tumours of WT mice [41], indicating that Hupki mice can reproduce TP53 hotspot 
alterations typically found in sunlight-exposed human skin of healthy individuals and of UV-
associated human tumours. In the only other in-vivo study performed thus far to examine TP53 
mutagenesis, no TP53 mutations were found in aflatoxin B1-induced liver tumours of Hupki mice, 
although these mice showed enhanced susceptibility to carcinogenesis relative to WT mice [109].  
 Hupki mice can also be genetically modified to express common human cancer-associated 
TP53 mutations in order to study their effect on tumourigenesis. By introducing the mutation into 
the humanised TP53 allele rather than WT mouse Tp53, the impact of the mutation on the structure 
and function of human p53 may be more accurately reproduced. Song et al. [112] engineered Hupki 
mice to express two of the most common p53 cancer mutants, R248W and R273H, designated  
TP53R248W and TP53R273H, respectively. TP53R248W mice developed tumours at a rate similar to 
Tp53-null mice (data for the tumourigenesis in TP53R273H mice was not presented). However, in 
addition to the thymomas and sarcomas formed in Tp53-null mice, TP53R248W mice also developed 
lymphomas and germ-cell tumours. The sarcomas in TP53R248W mice included haemangiosarcomas 
and rhabdomyosarcomas, which are rarely observed in Tp53-null mice. This difference in tumour 
spectrum suggests a gain-of-function activity for the R248W mutation. The authors went on to 
show that cells expressing the R248W or R273H mutants had enhanced genetic instability and an 
impaired DNA damage response. It would be interesting to see how other TP53 mutations 
expressed in the Hupki mouse model affect p53 activity and tumour development. 
 
Codon 72 polymorphic variants of the Hupki mouse 
 A common polymorphism occurs at codon 72 in TP53, resulting in either a proline (Pro72) 
or an arginine (Arg72). This occurs in the region of the gene encoding the polyproline domain, 
which is important for the apoptotic functions of p53 [113]. Interestingly, the polymorphism has 
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been suggested to influence the biology of p53 and selection of TP53 mutations and, in turn, cancer 
risk and response to therapy [114]. The original Hupki mouse contains Arg72, but Pro72 and 
Pro/Arg72 variant strains have been generated subsequently [57]. HUFs from these mice can be 
used to study the mutability of the polymorphic alleles and their impact on normal and mutant p53 
function. 
 There is some evidence that the Arg72 variant of p53 may be better at inducing apoptosis. 
Using cancer cell lines engineered to express either the Pro72 or Arg72 variant of p53 (referred to 
here as p53-Pro72 and p53-Arg72, respectively), p53-Arg72 was at least five times better at 
inducing apoptosis than p53-Pro72 [115]. The difference was associated with enhanced localisation 
of p53-Arg72 to the mitochondria. A study by Bonafe et al. [116] showed that normal cells 
expressing the p53-Arg72 variant have increased apoptosis in response to oxidative stress compared 
with cells expressing p53-Pro72, but this was only significant in cells from older patients.  
 If p53-Arg72 has an enhanced ability to induce apoptosis, it might be better able to protect 
individuals from cancer by eliminating damaged cells, but mutations on this allele may then be 
preferentially selected for. Some studies have indeed reported more frequent mutation of the Arg72 
allele in cancer [117,118]. Additionally, it was found that mutant p53-Arg72 binds more strongly to 
and inhibits p73 than does mutant p53-Pro72, leading to gain-of-function activity and a selective 
growth advantage [117]. However, there are other studies showing that the Pro72 allele is more 
frequently mutated in human tumours [119-121].  
 HUFs containing the three allelic configurations of the codon 72 polymorphism (Pro/Pro, 
Arg/Arg, Pro/Arg) can be used to study various hypotheses regarding the effect of this 
polymorphism in the selection of mutations on the variant alleles, as well as in p53 apoptotic 
function. For example, heterozygous HupkiPro/Arg72 HUFs could be used to determine whether 
mutations on one variant allele are more frequently selected for in the immortalisation assay. 
Interestingly, a study on AA-induced mutations by Reinbold et al. [57] showed a trend for more 
frequent mutation of the proline allele, with corresponding loss of the arginine allele in 
immortalised HupkiPro/Arg72 fibroblasts. As another possibility, HUF cell lines generated in the 
mutagenesis assay which contain TP53 mutations in cis with either the Pro72 or Arg72 
polymorphism could be used to assess how the polymorphism influences the activities of mutant 
p53. 
 
Concluding remarks 
With the mutagenic agents examined thus far, all of which are strongly genotoxic, it is 
apparent that the HUF immortalisation assay has sufficient specificity to make it applicable to a 
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wide range of other agents that putatively play a role in the aetiology of human cancer. Comparison 
of the TP53 mutation spectra generated by the in-vitro assay with the spectra of mutations in human 
tumours may test such hypotheses. Nevertheless, it is apparent from the studies conducted to date 
that there is considerable scope for improving both the sensitivity of the assay (the number of TP53 
mutants generated in each assay are relatively few) and its selectivity (only a proportion of the 
immortalised HUF clones actually contain mutated TP53). Further development of the assay to 
address these shortcomings offers the possibility of wider application of the assay to investigate 
some of the many outstanding uncertainties about cancer aetiology, in ways that are closely related 
mechanistically to the molecular pathology of the disease. 
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Legend to Figures: 
 
Figure 1: 
Generation of the human TP53 knock-in (Hupki) mouse (adapted from reference [38]). A targeting 
vector was created containing (i) exons 2−3 of mouse Tp53 sequence, (ii) a loxP-flanked neomycin 
(Neo) resistance cassette, (iii) exons 4−9 (and flanking introns) of human TP53, and (iv) exon 10 of 
mouse Tp53. The targeting vector was electroporated into embryonic stem (ES) cells which were 
subsequently selected for neomycin resistance and screened for recombination at exons 2−3 and 
exon 10 by PCR and Southern blotting. Correctly targeted ES clones were transfected with a Cre-
expressing vector to delete the loxP-flanked neomycin cassette, yielding the final human TP53 
knock-in (Hupki) allele. ES clones with the Hupki allele were injected into C57BL/6 blastocysts to 
generate chimeric mice, which were then backcrossed to 129/Sv mice. 
 
Figure 2: 
Experimental scheme of the HUF immortalisation assay. Primary fibroblasts are isolated from 
Hupki mouse embryos (passage 0) and seeded on multi-well plates (i.e. 40,000 cells/well on 24-
well plates or 200,000 cells/well on 6-well plates). Cells are treated with a test agent (e.g. 
environmental mutagen) at passage 0 or 1 (control cultures are treated with solvent). Cells are then 
serially passaged at 20% oxygen until the majority of each culture undergoes senescent crisis due to 
oxidative stress (between passage 4 to 8). Cells that have not senesced will continue to grow and 
will emerge as immortalised, clonal cell lines after at least 10 passages. These cultures often contain 
missense mutations in TP53. Isolated DNA is sequenced for mutations in TP53 to assess the effect 
of the mutagen on the pattern and spectrum of mutations. Inserts: Morphology of HUFs at different 
stages of the HUF immortalisation assay. Photomicrographs of cells growing in adherent 
monolayers were taken at 10× magnification. Primary HUFs become enlarged and flattened during 
senescence. Cells which bypass senescence grow into immortalised clonal populations of 
homogenous appearance; different sizes and morphologies of immortalised clones are observed 
(data not shown). 
 
Figure 3: 
Comparison of the types of TP53 base substitutions found in immortalised HUF cell lines treated 
with UV light [54], B[a]P [55,57], 3-NBA [59] or AAI [54,56,58]. Also shown is the mutation 
pattern in spontaneous immortalised HUFs (controls) [53].  
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Figure 4: 
Environmental carcinogens that have been investigated in the HUF immortalisation assay, their 
major sites of DNA modification, and major type of induced mutation. DNA adducts have been 
structurally identified as: (6-4)PP, (6-4) pyrimidine-pyrimidone photoproduct; CPD, cyclobutane 
pyrimidine dimer; dG-N2-BPDE, 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene; dG-N2-3-ABA, 2-(2’-deoxyguanosin-N2-yl)-3-aminobenzanthrone; dG-
C8-N-3-ABA, N-(2’-deoxyguanosin-8-yl)-3-aminobenzanthrone; dA-AAI, 7-(deoxyadenosin-N6-
yl)aristolactam I. 
 
Figure 5: 
Mutation pattern and spectra of TP53 mutations in immortalised HUF cell lines treated with B[a]P 
(A) [55,57; Monica Hollstein, personal communication] or 3-NBA (C) [59]. Also shown is the 
mutation pattern and spectra of TP53 mutations in spontaneously immortalised HUFs (controls) (E) 
[53]. TP53 mutation pattern and spectra in lung cancer of smokers (B) or nonsmokers (D). Mutation 
data from human tumours were obtained from the IARC TP53 mutation database (www.p53.iarc.fr; 
R13 version). Entries with confounding exposure to asbestos, mustard gas or radon were excluded. 
Note that in the mutations spectrum only single base substitutions in codons are shown here; single 
base substitution detected for instance at splice sites are not depicted. 
 
Figure 6: 
(A) Mutation pattern and spectrum of TP53 mutations in immortalised HUF cell lines treated with 
AAI [54,56,58]. (B) TP53 mutation pattern and spectra in BEN-associated urothelial cancer [27]. 
Codons containing A to T transverion mutations are indicated by asterisks (*). (C) TP53 mutation 
pattern and spectra in urothelial cancer not associated with AA exposure. Mutation data from 
human tumours were obtained from the IARC TP53 mutation database (www.p53.iarc.fr; R13 
version). Organs included are kidney, bladder, renal pelvis, ureter and other urinary organs. 
Morphology inclusion criteria: carcinoma not otherwise specified, carcinoma in situ not otherwise 
specified, dysplasia not otherwise specified, papillary carcinoma not otherwise specified, papillary 
transitional cell carcinoma, transitional cell carcinoma not otherwise specified, transitional cell 
carcinoma in situ, squamous cell carcinoma not otherwise specified, and urothelial papilloma not 
otherwise specified. Note that in the mutation spectrum only single base substitutions in codons are 
shown here; single base substitution detected for instance at splice sites are not depicted. 
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